<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675751</url>
  </required_header>
  <id_info>
    <org_study_id>STAR-115-MIPS</org_study_id>
    <nct_id>NCT02675751</nct_id>
  </id_info>
  <brief_title>Prospective S&amp;E Study of Wavefront-guided PRK for Myopia With iDesign Advanced Wavescan Studio™ System and Star S4 IR™</brief_title>
  <official_title>A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-guided PRK Correction of Myopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and the Star S4 IR™ Excimer Laser System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Optics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, bilaterally-treated, open-label, non-randomized clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 3, 2016</start_date>
  <completion_date type="Actual">July 27, 2018</completion_date>
  <primary_completion_date type="Actual">July 27, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Eyes Achieving the Target of Monocular Uncorrected Visual Acuity of 20/40 or Better</measure>
    <time_frame>6 months</time_frame>
    <description>At 6 months, UCVA of 20/40 was achieved in 100% (324/324) of eyes monocularly.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Stable Myopic Refractive Error, With or Without Astigmatism</condition>
  <arm_group>
    <arm_group_label>wavefront-guided PRK with iDesign</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>wavefront-guided PRK for treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>STAR S4 IR laser with iDesign</intervention_name>
    <description>Surgeons will perform wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser.</description>
    <arm_group_label>wavefront-guided PRK with iDesign</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        NOTE: Enrollment open only to military personnel

        Inclusion Criteria:

          -  Signed informed consent and HIPAA authorization.

          -  Refractive error, based on the iDesign displayed refraction must be myopia with or
             without astigmatism with sphere up to -8.00 D, and cylinder between 0.00 D and -4.00 D
             with maximum SE of -10.00 D.

          -  Anticipated residual stromal bed thickness of at least 250 microns as calculated by
             the iDesign system.

          -  Distance Best Spectacle Corrected Visual Acuity (BSCVA) of 20/20 or better

          -  BSCVA ≥2 lines (≥10 letters) better than distance Uncorrected Visual Acuity (UCVA).

          -  Less than or equal to 0.75 D difference between cycloplegic and manifest refraction
             sphere.

          -  Stable refractive error as defined by a change of ≤1.00 D in MRSE over at least a 12
             month time period.

          -  Any subject eye with a history of contact lens wear within the last 4 weeks must
             demonstrate refractive stability

          -  Agreement between manifest refraction (adjusted for optical infinity) and iDesign
             System refraction chosen for treatment.

          -  Willing and capable of complying with follow-up examinations for the duration of the
             study.

        Exclusion Criteria:

          -  Women who are pregnant, breast-feeding, or intend to become pregnant, or not using an
             adequate method of birth control.

          -  Concurrent use of systemic (including inhaled) medications that may impair healing.

          -  History of any of the following medical conditions, or any other condition that could
             affect wound healing: collagen vascular disease, autoimmune disease, immunodeficiency
             diseases, ocular herpes zoster or herpes simplex, endocrine disorders (including, but
             not limited to unstable thyroid disorders and diabetes), lupus, and rheumatoid
             arthritis.

          -  Subjects with a cardiac pacemaker, implanted defibrillator or other implanted
             electronic device.

          -  History of prior intraocular or corneal surgery, active ophthalmic disease or
             abnormality, retinal detachment/repair, clinically significant lens opacity, clinical
             evidence of trauma, corneal opacity within the central 9 mm and visible on topography,
             at risk for developing strabismus, or with evidence of glaucoma or propensity for
             narrow angle glaucoma.

          -  Evidence of keratoconus, corneal dystrophy or irregularity, or abnormal topography

          -  Known sensitivity or inappropriate responsiveness to any of the medications used in
             this study.

          -  If either eye does not meet all inclusion criteria

          -  Desire to have monovision.

          -  Participation in any other clinical study, with the exception of the fellow eye in
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Tarantino, OD</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Surgical Vision, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Naval Hospital Camp Pendleton</name>
      <address>
        <city>Camp Pendleton</city>
        <state>California</state>
        <zip>92055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warfighter Eye Center Malcolm Grow Medical Clinics and Surgery Center</name>
      <address>
        <city>Andrews Air Force Base</city>
        <state>Maryland</state>
        <zip>20762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Hospital Camp LeJeune</name>
      <address>
        <city>Camp Lejeune</city>
        <state>North Carolina</state>
        <zip>28547</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Army Medical Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint Warfighter Refractive Surgery Center Wilford Hall Medical Center</name>
      <address>
        <city>Lackland Air Force Base</city>
        <state>Texas</state>
        <zip>78236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center Portsmouth</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <results_first_submitted>July 23, 2019</results_first_submitted>
  <results_first_submitted_qc>September 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 24, 2019</results_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myopia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 17, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT02675751/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 18, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT02675751/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>235 subjects were consented in the study, of which all 167 subjects have both eyes treated for a total of 334 treated eyes.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PRK Correction With iDesign System and STAR S4 IR Laser</title>
          <description>Surgeons performed wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PRK Correction With iDesign System and STAR S4 IR Laser</title>
          <description>Surgeons performed wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="167"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Eyes</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="334"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" spread="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Eyes Achieving the Target of Monocular Uncorrected Visual Acuity of 20/40 or Better</title>
        <description>At 6 months, UCVA of 20/40 was achieved in 100% (324/324) of eyes monocularly.</description>
        <time_frame>6 months</time_frame>
        <population>Of the 334 eyes (167 subjects) treated in the study, 324 eyes (162 subjects) were available at 6 months for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PRK Correction With iDesign System and STAR S4 IR Laser</title>
            <description>Surgeons performed wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Eyes Achieving the Target of Monocular Uncorrected Visual Acuity of 20/40 or Better</title>
          <description>At 6 months, UCVA of 20/40 was achieved in 100% (324/324) of eyes monocularly.</description>
          <population>Of the 334 eyes (167 subjects) treated in the study, 324 eyes (162 subjects) were available at 6 months for analysis.</population>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Number of eyes with UCVA of 20/40 or better</title>
                  <measurement_list>
                    <measurement group_id="O1" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PRK Correction With iDesign System and STAR S4 IR Laser</title>
          <description>Surgeons performed wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Anterior Uveitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Corneal Abrasions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Corneal Infiltrate</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Corneal Haze</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Corneal Erosion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must review results communications prior to public release and can embargo communications regarding trial results at any time.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sanjeev Kasthurirangan Ph.D.</name_or_title>
      <organization>Johnson &amp; Johnson Surgical Vision</organization>
      <phone>+1 408-273-4081</phone>
      <email>skasthur@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

